USD 11.3
(1.07%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 8.76 Billion USD | -1.72% |
2022 | 8.91 Billion USD | -2.42% |
2021 | 9.13 Billion USD | 29364.52% |
2020 | 31 Million USD | -70.19% |
2019 | 104 Million USD | -30.2% |
2018 | 149 Million USD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | 8.71 Billion USD | -0.53% |
2024 Q3 | 8.74 Million USD | 1.07% |
2024 Q2 | 8.65 Billion USD | -0.67% |
2023 Q1 | 8.71 Billion USD | -2.27% |
2023 FY | 8.76 Billion USD | -1.72% |
2023 Q4 | 8.76 Billion USD | 1.22% |
2023 Q3 | 8.65 Billion USD | -0.87% |
2023 Q2 | 8.73 Billion USD | 0.22% |
2022 Q3 | 8.69 Billion USD | -2.18% |
2022 Q2 | 8.89 Billion USD | -2.21% |
2022 Q1 | 9.09 Billion USD | -0.44% |
2022 FY | 8.91 Billion USD | -2.42% |
2022 Q4 | 8.91 Billion USD | 2.46% |
2021 Q3 | 9.29 Billion USD | -0.53% |
2021 Q2 | 9.34 Billion USD | 515.0% |
2021 FY | 9.13 Billion USD | 29364.52% |
2021 Q1 | 1.52 Billion USD | 13.52% |
2021 Q4 | 9.13 Billion USD | -1.76% |
2020 Q4 | 1.33 Billion USD | 0.0% |
2020 FY | 31 Million USD | -70.19% |
2020 Q1 | - USD | 0.0% |
2019 FY | 104 Million USD | -30.2% |
2018 FY | 149 Million USD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
AbbVie Inc. | 59.38 Billion USD | 85.249% |
Bristol-Myers Squibb Company | 41.46 Billion USD | 78.873% |
Bristol-Myers Squibb Company Ce | 41.46 Billion USD | 78.873% |
Johnson & Johnson | 29.33 Billion USD | 70.135% |
Eli Lilly and Company | 25.22 Billion USD | 65.273% |
Merck & Co., Inc. | 36.26 Billion USD | 75.846% |
Novartis AG | 26.34 Billion USD | 66.753% |
Pfizer Inc. | 75.04 Billion USD | 88.326% |